Insmed (NASDAQ:INSM) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report issued on Wednesday.
A number of other brokerages have also recently commented on INSM. Robert W. Baird reaffirmed a “positive” rating and set a $42.00 price objective (up from $32.00) on shares of Insmed in a research note on Thursday, January 4th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Insmed in a research note on Thursday, January 4th. Zacks Investment Research cut Insmed from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Credit Suisse Group assumed coverage on Insmed in a research note on Wednesday, January 17th. They set a “neutral” rating and a $31.00 price objective for the company. Finally, ValuEngine raised Insmed from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. Insmed has an average rating of “Buy” and a consensus target price of $36.90.
Shares of Insmed stock opened at $23.85 on Wednesday. The company has a quick ratio of 8.72, a current ratio of 8.72 and a debt-to-equity ratio of 0.15. Insmed has a 12 month low of $11.49 and a 12 month high of $33.94. The firm has a market cap of $1,736.28, a P/E ratio of -8.25 and a beta of 1.11.
Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Friday, February 23rd. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). equities research analysts anticipate that Insmed will post -3.8 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of INSM. Janus Henderson Group PLC grew its stake in Insmed by 140.2% in the third quarter. Janus Henderson Group PLC now owns 3,960,748 shares of the biopharmaceutical company’s stock valued at $123,615,000 after acquiring an additional 2,312,045 shares during the period. BlackRock Inc. grew its stake in Insmed by 11.7% in the fourth quarter. BlackRock Inc. now owns 7,830,604 shares of the biopharmaceutical company’s stock valued at $244,159,000 after acquiring an additional 817,915 shares during the period. Nexthera Capital LP grew its stake in Insmed by 246.5% in the fourth quarter. Nexthera Capital LP now owns 498,921 shares of the biopharmaceutical company’s stock valued at $15,556,000 after acquiring an additional 354,921 shares during the period. Redmile Group LLC grew its stake in Insmed by 12.9% in the fourth quarter. Redmile Group LLC now owns 2,249,262 shares of the biopharmaceutical company’s stock valued at $70,132,000 after acquiring an additional 257,616 shares during the period. Finally, Palo Alto Investors LLC grew its stake in Insmed by 3.8% in the fourth quarter. Palo Alto Investors LLC now owns 6,404,586 shares of the biopharmaceutical company’s stock valued at $199,695,000 after acquiring an additional 232,770 shares during the period. 99.08% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/13/insmed-insm-rating-increased-to-hold-at-bidaskclub.html.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.